Testing the Effects of Anti-DLL4 Monoclonal Antibody in Conjunction With Tamoxifen Hormone Therapy Treated Ovarian Cancer
ISEF · 2022 Biomedical and Health Sciences
Overview
Hormone therapy is commonly used to treat hormone-related cancers and there has been previous research which suggests that monoclonal antibodies (mAbs) have had a positive therapeutic effect on ovarian cancer, but further investigations need to be conducted to establish a more defined treatment. This experiment will test the effects of Anti-DLL4 mAb that has shown a positive therapeutic effect on ovarian cancer that is currently receiving tamoxifen hormone therapy to see what effect the mAbs will have on the inhibition of tamoxifen-treated ovarian cancer. The researcher’s hypotheses are, first, if Anti-DLL4 mAb is introduced to tamoxifen-treated ovarian cancer cells, then it will inhibit growth in ovarian cancer cells, and, second, if 5uL, 8uL, and 10uL of Anti-DLL4 mAb are introduced to tamoxifen-treated ovarian cancer cells, then the sample of cells with 8uL of Anti-DLL4 mAb will inhibit the most growth in the cells because it is most closely follows the recommended dosage of Anti-DLL4 mAb. The researcher cultured and subcultured the cells into five separate flasks and applied treatments accordingly for use in each of the different experimental groups: control, 7uL tamoxifen control, 5uL mAb + 7uL tamoxifen, 8uL mAb + 7uL tamoxifen, and 10uL mAb + 7uL tamoxifen. The researcher utilized a hemocytometer in order to obtain quantitative data through cell counts; the cell counts were taken directly after the treatments were applied, after 24 hours, and after 48 hours. The most cell growth inhibition was seen in the 8uL mAb + 7uL tamoxifen treatment group, proving the researcher’s hypothesis was correct and establishing that this can be used as a therapeutic treatment for patients with ovarian cancer.
Competition history
- ISEF 2022
Resources
Related projects
ISEF · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2018
Inhibitor A: Targeting Therapeutically Resistant HER2+ Breast Cancer Tissues
ISEF · 2018
New Potential Therapy for Ovarian Cancer: Stearoyl-CoA Desaturase-1 (SCD1) Inhibition with the Novel Compound SSI-4
ISEF · 2014
Seeking a Cure II: Targeting ERß in a Novel Cost-Effective Treatment for Ovarian Epithelial Cancer
ISEF · 2023
The Effects of APC Loss on Response to Chemotherapy in Ovarian Cancer Cells
ISEF · 2016
Investigating a Novel Treatment for Breast Cancer Brain Metastasis: The Alpha-v Integrin Inhibitor Cilengitide Potentiates Cisplatin Chemotherapy
JSHS · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2024
The Impact of Paclitaxel and Doxorubicin on APC Knockout Cells in Breast Cancer
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair